Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT04400201
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04400188
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04400123
- Locations
- 🇨🇳
Xuanwu Hospital Beijing, Capital Medical University, Beijing, Beijing, China
A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04395053
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT04390984
- Locations
- 🇨🇳
Sun Yat-Sen Univercity Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT04390295
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat - sen University, Guangzhou, Guangdong, China
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults
Phase 2
- Conditions
- Preoperative Sedation
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT04383418
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04383977
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04367090
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 233
- Registration Number
- NCT04346381
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath